| GOLD + SYMPOSIUM SPONSOR |
|
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and connectivity solutions. In 1995, Masimo debuted SET® Measure-through Motion and Low Perfusion™ pulse oximetry, estimated to be used on more than 100 million patients annually. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of additional physiologic parameters that previously could only be measured invasively, such as total hemoglobin (SpHb®). We continue to advance noninvasive monitoring, connectivity, and automation with innovations like the Root® patient monitoring and connectivity hub and the Patient SafetyNet™ supplemental remote monitoring solution. |
| GOLD |
|
What’s happening in the brain may tell us what’s happening in the rest of the body. Our technology is designed to provide reliable, real-time insights that help support your decision-making. Because to help prevent complications, achieve better patient outcomes, and lower the overall cost of care, relying on instincts may not always be enough. Our products include INVOSTM Regional oximetry and BISTM level of sedation monitoring. |
| SYMPOSIUM SPONSOR |
|
Medasense is transforming the way PAIN is being assessed and treated worldwide. Through our breakthrough NOL® AI technology and sensing platform, the PMD-200™ nociception monitoring device quantifies pain response in patients under general anesthesia, enabling clinicians to personalize pain management, support opioid sparing and improve postoperative recovery. The PMD-200™ is the first and only pain measurement device for anesthesiology to be authorized by the FDA. Clinical studies have demonstrated its impact on patient safety and outcomes. With over 70,000 patients already treated worldwide, and more than 40 published articles, NOL monitoring has proven its effectiveness in perioperative care. Visit www.medasense.com for clinical resources and additional information. |
| EXHIBITOR |
| Seattle-based, TOF industry expert. Maker of TwitchView, the clinically validated electromyography (EMG) train of four (TOF) monitor with dynamic real-time and trended displays. Studies demonstrate that using the TwitchView can improve management of neuromuscular blockade, optimize antagonism and eliminate residual neuromuscular blockade. Easy to place electrodes for infant, pediatric and adult patients and a one-button startup minimize workflow disruptions, while continuous AutoPTCTM monitoring and EMR integration eliminate manual user tasks. Blink DC will partner with your organization to make quantitative monitoring with TwitchView a standard of care. |
| EXHIBITOR |
| Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com . |
| EXHIBITOR |
| For more than 50 years, Edwards Lifesciences has been helping you make proactive clinical decisions and advance the care of surgical and acutely ill patients across the continuum of care. Through ongoing collaboration with clinicians, providing continuous education, and our dedication to purposeful innovation, Edwards continues to develop smart hemodynamic management solutions that enable proactive decision support. |
| EXHIBITOR |
|
Infosys is a global leader in next-generation digital services and consulting. We enable clients in more than 50 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem. Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next. |
| EXHIBITOR |
| For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. |
| EXHIBITOR |
|
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing non-opioid options to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid options for treating pain: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com. Company Websites: www.EXPAREL.com www.iovera.com www.zilretta.com |
| EXHIBITOR |
| Renibus is dedicated to treating, improving and extending patients’ lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases. Renibus’ first-in-class lead program, RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. RBT-1 has finished its Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. |
| EXHIBITOR |
|
Retia Medical is a leading manufacturer of Hemodynamic monitors that provide accurate and consistent data to help clinicians improve outcomes for high-risk patients. Through its MBA technology, The Argos monitor analyzes multiple heartbeat at a time allowing for a more accurate modeling of a patient’s own circulatory system while eliminating the need for costly disposables. |
| EXHIBITOR |
| Deployed by leading health systems, SeamlessMD provides a Digital Care Journey and Remote Monitoring platform for ERAS. Supporting multiple service lines, the platform delivers standardized, interactive patient education, ERAS protocol reminders, ERAS compliance tracking, and automated PRO data collection. 35+ clinical studies have shown SeamlessMD to reduce hospital LOS, readmissions, ED visits, and costs. For more information, visit www.seamless.md |